Jaguar Health (JAGX) Return on Sales (2015 - 2026)

Jaguar Health (JAGX) has 12 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales rose 5.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.05%, down 1.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.07% in the prior quarter.
• Over the last five years, Return on Sales for JAGX reached as high as 0.0% in Q1 2026 and fell as low as 9.08% in Q1 2022.
• Historically, Return on Sales has averaged 0.88% across 5 years, with a median of 0.04% in 2024.
• Across the five-year window, Return on Sales sank 898 bps in 2022 and soared 633 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 2.57% in 2022, then surged by 98 bps to 0.04% in 2023, then advanced by 28 bps to 0.03% in 2024, then slumped by 146 bps to 0.07% in 2025, then jumped by 106 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.07% in Q4 2025, and 0.03% in Q3 2025.